Scientific Advisors

Michael Gantier 

Associate Professor, Research Group Head, Nucleic Acids and Innate Immunity

Associate Professor Michael Gantier leads the Nucleic Acids and Innate Immunity laboratory in the Centre for Innate Immunity and Infectious Disease at the Hudson Institute of Medical Research. The central theme of his research is to define how nucleic acids (RNA and DNA) modulate immune responses. He was trained as a biological engineer in Compiegne, France, prior to undertaking his PhD in Medicine and Therapeutics in University College Dublin Ireland with Prof. Seamas Donnelly, working on the then emerging RNA interference technology. Following on his PhD studies he joined the laboratory of Prof Bryan Williams in 2006, to define the interaction of RNAs with the innate immune system. This led to the discoveries of structural determinants of RNAs which underlie their capacity to activate or inhibit immune responses by Toll Like Receptors, a theme he has developed further in his independent laboratory since 2015. More recently, his laboratory discovered how immune responses could be engaged in damaged cells, with implications in infection, immunity, and cancer - through the engagement of the cGAS-STING pathway. In 2015, following the award of an ARC Future Fellowship and several NHMRC project grants, he was promoted to lead his own research group in the Hudson Institute of Medical Research and in 2020 was promoted to Associate Professor. He received the prestigious Milstein Young Investigator award from the International Cytokine and Interferon Society (2010), and Oligonucleotide Therapeutics Society Young Investigator award (2014) among several other international and national awards. He has published over 70 peer-reviewed publications, and is an inventor on 5 PCT patents. Two of these patents were recently licensed to the biotech company Pharmorage. He currently serves as Associate Editor for the prestigious journal Molecular Therapy-Nucleic Acids and the Journal of Interferon and Cytokine Research.

Read more

Lorenzo Galluzzi 

Assistant Professor of Cell Biology in Radiation Oncology

Lorenzo Galluzzi (born 1980) is currently Assistant Professor of Cell Biology in Radiation Oncology with the Department of Radiation Oncology of the Weill Cornell Medical College (New York, NY, USA), Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine (New Haven, CT, USA), and Assistant Professor of Cell and Developmental Biology with the Graduate School of Medical Sciences of the Weill Cornell Medical College (New York, NY, USA), as well as Faculty Member with Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara (Ferrara, Italy), the Graduate School of Pharmacological Sciences of the University of Padova (Padova, Italy), and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza” (Rome, Italy). Prior to joining Weill Cornell Medical College (2017), Lorenzo Galluzzi was a Junior Scientist of the Research Team “Apoptosis, Cancer and Immunity” at the Cordeliers Research Center (Paris, France; 2012-2016). Lorenzo Galluzzi did his post-doctoral training at the Gustave Roussy Comprehensive Cancer Center (Villejuif, France; 2009-2011), after receiving his PhD from the University Paris Sud (Le Kremlin-Bicetre, France; 2005-2008). He is also Associate Director of the European Academy for Tumor Immunology (EATI), and Founding Member of the European Research Institute for Integrated Cellular Pathology (ERI-ICP). Lorenzo Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. In particular, he provided profound insights into the links between adaptive stress responses in cancer cells and the activation of a clinically relevant tumor-targeting immune response in the context of chemotherapy and radiation therapy. Lorenzo Galluzzi has published more than 500 scientific articles in international peer-reviewed journals. According to a survey published by Lab Times, he was the 6th and the youngest of the 30 most-cited European cell biologists (for the period 2007–2013), and he has been nominated Highly Cited Researcher by Clarivate Analytics (formerly, Thomson Reuter) in 2016 (Biology & Biochemistry), 2018 (Cross-Fields), 2019 (Immunology and Molecular Biology & Genetics), 2020 (Immunology and Molecular Biology & Genetics) and 2021 (Immunology, Molecular Biology & Genetics and Pharmacology/Toxicity, an honor shared with only 22 other scientists worldwide, all disciplines confounded). Lorenzo Galluzzi currently operates as Editor-in-Chief of four journals: OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell Biology, and Molecular and Cellular Oncology (which he co-founded in 2013). In addition, Lorenzo Galluzzi currently serves as Founding Editor for Microbial Cell and Cell Stress, Associate Editor for Cell Death and Disease and Aging, Section Editor for Cells, and Guest Editor for Methods in Enzymology.

Read more

Marcel Nold 

Professor of Paediatric Immunology and Consultant Neonatal Paediatrician

MD, FRACP I am a clinician-scientist, pediatrician and neonatologist. My work, carried out in Germany, the USA and for the last ~12 years in Australia, is focused on interventional immunology and anti-inflammatory cytokines, and has attracted the interest of opinion-leading journals and pharmaceutical companies. I am passionate about my research making a meaningful difference to my patients and their families. Therefore, aiming to lay the foundations for and then establish much-needed new therapies, I employ bedside-to-bench-and-back approaches to explore the molecular mechanisms underpinning severe illnesses that affect infants and children, such as neonatal chronic lung disease, pulmonary hypertension, necrotizing enterocolitis, and intracranial/intraventricular hemorrhage. In addition to early life-diseases, my work in translational molecular medicine aspires to develop and advance novel cytokine-based therapeutics towards clinical application, thus bringing urgently needed relief to patients with autoinflammatory and autoimmune illnesses such as systemic lupus erythematosus as well as viral illnesses such as influenza and Covid-19.

Read more